Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1383&sort=-program_reference_codes
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-program_reference_codes", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1397&sort=-program_reference_codes", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=-program_reference_codes", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1382&sort=-program_reference_codes" }, "data": [ { "type": "Grant", "id": "11641", "attributes": { "award_id": "5R01NR019831-02", "title": "A Multisite Randomized Controlled Trial of EMPOWER for Family Surrogates of Critically Ill Patients", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Nursing Research (NINR)" ], "program_reference_codes": [], "program_officials": [ { "id": 6036, "first_name": "Karen", "last_name": "Kehl", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-01", "end_date": "2026-01-31", "award_amount": 773616, "principal_investigator": { "id": 23783, "first_name": "Wendy G.", "last_name": "Lichtenthal", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 825, "ror": "", "name": "WEILL MEDICAL COLL OF CORNELL UNIV", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 27546, "first_name": "Holly Gwen", "last_name": "Prigerson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 825, "ror": "", "name": "WEILL MEDICAL COLL OF CORNELL UNIV", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Intensive Care Units (ICUs) are stressful places fraught with grief and potentially traumatic exposures for those witnessing a critically ill family member in pain, struggling to breathe, maintain consciousness, and stay alive. Compounding their distress, family caregivers are often thrust into the position of patient “surrogate,” needing to make life-and-death decisions on the patient's behalf. We have shown that end-of-life (EoL) decision-making is compromised by elevated symptoms of distressing and disabling grief, resulting in family surrogates making suboptimal EoL choices that often prolong patient suffering, further exacerbating surrogates' grief, trauma, and regrets. The coronavirus (COVID-19) pandemic has made this bad situation worse, particularly among Black, Indigenous, and People of Color (BIPOC). Prior efforts to address the plight of these family surrogates have proved disappointing, with some significantly worsening surrogates' psychological trauma. Yet these were not psychological interventions, much less ones using psychological techniques with proven efficacy. To address these shortcomings, we developed a brief, flexibly administered intervention applying empirically supported cognitive-behavioral and acceptance-based techniques. In an R21 pilot, this intervention, EMPOWER (Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience), dramatically reduced experiential avoidance, grief, and traumatic stress, and was associated with higher rates of advance care planning, including among BIPOC. The proposed multisite, mixed-methods trial will randomize 172 family surrogates to receive EMPOWER (N=86) or a standardized supportive conversation (SC; N=86) delivered via videoconferencing. Surrogate symptoms will be assessed pre-intervention, immediately post-intervention, and 3- and 12-months post-intervention. The primary aim of this study is to compare the efficacy of EMPOWER to SC. We hypothesize that, compared to SC, EMPOWER will yield significantly greater declines in H1a. surrogate grief and posttraumatic stress (primary outcomes) and H1b. experiential avoidance, depression, regrets, and increase patients' receipt of value concordant care (secondary outcomes). The secondary aim of this study is to contextualize quantitative RCT results. H2. Qualitative interviews will provide complementary data on perceived barriers to and facilitators of symptom improvement, dissemination, and implementation, as well as insights into the impact of medical mistrust, perceived discrimination and COVID-19 on outcomes. The third aim will explore experiential avoidance as a mediator of intervention effects: H3. Reductions in experien- tial avoidance will mediate reductions in grief and posttraumatic stress. This study is expected to confirm EMPOWER's efficacy and enhance understanding of ways to improve telehealth delivery to psychologically vulnerable and historically underserved surrogates. If successful, EMPOWER will address the urgent need for effective, culturally competent interventions for distressed surrogates, which may improve critically ill patients' EoL experience in the context of extreme challenges that have been exacerbated by the COVID-19 pandemic.", "keywords": [ "Address", "Advance Care Planning", "Affect", "Anger", "Behavioral", "Bereavement", "Black race", "Black Indigenous People of Color", "Breathing", "COVID-19", "COVID-19 pandemic", "COVID-19 patient", "Caregivers", "Caring", "Cessation of life", "Cognitive", "Communication", "Confusion", "Conscious", "Coronavirus", "Critical Illness", "Data", "Decision Making", "Disease", "Disorientation", "Dissemination and Implementation", "Distress", "Emotional", "Equipment and supply inventories", "Family", "Family Caregiver", "Family health status", "Family member", "Feeling", "Goals", "Grief reaction", "Guilt", "Hospitals", "Indigenous", "Intensive Care Units", "Intervention", "Interview", "Left", "Life", "Life Experience", "Loneliness", "Mediating", "Mediation", "Mediator", "Medical", "Medical center", "Memorial Sloan-Kettering Cancer Center", "Mental Depression", "Mental Health", "Methods", "Modeling", "Numbness", "Outcome", "Pain", "Palliative Care", "Parents", "Patient Care", "Patients", "Persons", "Positioning Attribute", "Post-Traumatic Stress Disorders", "Presbyterian Church", "Psychological Techniques", "Psychological adjustment", "Quality of Care", "Race", "Randomized", "Randomized Controlled Trials", "Regrets", "Reporting", "Risk", "Role", "Severities", "Site", "Social Distance", "Standardization", "Structure", "Symptoms", "Techniques", "Thinking", "Trauma", "United States", "United States National Institutes of Health", "Videoconferencing", "comparative efficacy", "contextual factors", "cultural competence", "disease transmission", "efficacy evaluation", "end of life", "end of life care", "experience", "flexibility", "future implementation", "improved", "insight", "intervention effect", "loved ones", "meetings", "pandemic disease", "people of color", "perceived discrimination", "post intervention", "post-traumatic stress", "post-traumatic symptoms", "primary outcome", "psychologic", "psychological distress", "psychological outcomes", "psychological trauma", "psychosocial", "racial disparity", "recruit", "reduce symptoms", "resilience", "secondary outcome", "stress symptom", "symptomatic improvement", "telehealth", "traumatic stress", "treatment as usual" ], "approved": true } }, { "type": "Grant", "id": "11642", "attributes": { "award_id": "5K01HS028926-02", "title": "Adapting Guideline Implementation to Local Environments (AGILE) in Primary Care After Telehealth Expansion", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Agency for Healthcare Research and Quality (AHRQ)" ], "program_reference_codes": [], "program_officials": [ { "id": 26676, "first_name": "Tamara", "last_name": "Willis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-08", "end_date": "2027-03-31", "award_amount": 159664, "principal_investigator": { "id": 23786, "first_name": "Edmond", "last_name": "Ramly", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 799, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 799, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT Urgent expansion of telehealth due to the COVID-19 pandemic may have consequences for evidence based primary care, including worsening disparities in cardiovascular disease (CVD) prevention. Implementing evidence based guidelines to reverse CVD risk would prevent more than 50% of annual deaths in middle-aged US adults but is already uneven. Guideline adherence can be improved by tailoring strategies to local barriers as in Dr. Ramly’s prior work that increased follow up on blood pressure and smoking with higher gains among Black patients. Yet tailoring is too expensive and burdensome to be used in practice and is even less feasible with the rapid telehealth expansion. There is a critical need for an alternative to tailoring to enable primary care clinics to rapidly adapt how they implement CVD guidelines after telehealth expansion to avoid worsening disparities. In engineering, configurable solutions make menus of options available to avoid expensive individual tailoring. This approach could enable clinics to use known strategies to address local barriers without engaging in an expert-led individual tailoring process. Preliminary qualitative work found many barriers to optimal care with telehealth that are modifiable with known strategies. Yet configurable solutions using known strategies have not been applied in health care despite the potential to reduce cost and reduce disparities by addressing local needs. Applying this approach will require multi-stakeholder design of a configurable toolkit informed by large clinical data and tested by a pragmatic clinical trial. Dr. Ramly’s long-term goal is to become a clinical investigator in primary care leading an independent research program to improve rapid implementation of evidence based care for chronic conditions. This 5-year K01 will fill his clinical investigation training gaps with mentored research and training in large clinical data, mixed methods, and pragmatic clinical trials. As a systems engineer faculty in a clinical department, Dr. Ramly is well prepared for a successful K01 to transition from engineer collaborator to independent clinical investigator. The overall objective of this proposal is to develop and pilot a configurable toolkit for CVD prevention. Four CVD quality metrics will be targeted: blood pressure control for patients with hypertension, and aspirin, statins, and smoking cessation for patients with coronary artery disease. The specific aims are to: 1) characterize barriers to implementation of CVD guidelines in primary care after telehealth expansion, 2) develop a configurable toolkit of strategies to address local barriers, and 3) pilot test the toolkit to assess reach, effectiveness, adoption, implementation, and maintenance, including subgroup differences. Expected outcomes are an intervention addressing a critical gap in evidence based care after telehealth expansion, with preliminary data for an AHRQ R18 trial. Dr. Ramly will become an independent clinical investigator building on prior expertise in engineering and implementation science. His current and future research aims will advance AHRQ’s mission by focusing on AHRQ-relevant priority populations (chronic conditions, older adults), problem (heart health) and emphasis (primary care).", "keywords": [], "approved": true } }, { "type": "Grant", "id": "11643", "attributes": { "award_id": "5T34GM136471-02", "title": "U-RISE Program at Fayetteville State University", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 27540, "first_name": "MARIE DEBORAHGAYNELLE", "last_name": "Harton", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-01", "end_date": "2027-03-31", "award_amount": 322072, "principal_investigator": { "id": 23787, "first_name": "James Edward", "last_name": "Raynor", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1639, "ror": "https://ror.org/03rj92e31", "name": "Fayetteville State University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1639, "ror": "https://ror.org/03rj92e31", "name": "Fayetteville State University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "Program Summary The U-RISE program will be located at Fayetteville State University (FSU), which is one of the 17 constituent institutions of the University of North Carolina System and the second oldest public institution of higher education in the state. The U-RISE program will be a research training program comprised of a series of evidence-based, phased-in awareness, mentoring and developmental activities designed to help students succeed in college, and transition into biomedical, research-focused, higher degree programs upon graduation. Underrepresented minority (URM) students from biology, chemistry, forensic science, math, and computer science majors will engage in intensive research training and professional development activities beginning at the college sophomore year through their acceptance into graduate schools. Each year of program matriculation, trainees will develop new skills and experiences to become more competitive applicants for graduate schools. In light of the recent COVID-19 pandemic, alternative virtual training activities have been proposed in the event future face-to-face meetings are prohibited. Based upon institutional assessments and the previous successful design of the FSU-RISE program, this application proposes to establish a U-RISE program at FSU with an overarching goals to develop an increased talent pool of well-trained URM students in biology, chemistry, forensic science and math and computer science in which at least 90% (27 of 30) will graduate with baccalaureate degrees from FSU with at least a 3.0 GPA; and at least 75% (23 of 30) will transition into biomedical, research- focused higher degree programs within the 5 years of funding. The following three objectives are proposed to achieve these goals: 1. To enhance the academic preparation of URM trainees in biology, chemistry, forensic science, mathematics, and computer science such that each year 2. To provide meaningful research training experiences to develop a well-prepared URM trainee pool of research-ready, critical and independent thinkers for competitive entry into biomedical research-focused higher degree programs each year 3. To engage trainees in cohort-building interventions each year to enhance self-efficacy and biomedical research-focused higher degree identity Trainees will be selected through a competitive application process, which includes meeting program criteria and performing well in an interview. Longitudinal, mixed-methods formative and summative evaluations will be conducted to evaluate measures/benchmarks and program effectiveness.", "keywords": [ "Awareness", "Bachelor&apos", "s Degree", "Benchmarking", "Biology", "Biomedical Research", "COVID-19 pandemic", "Chemistry", "Degree program", "Development", "Evaluation", "Event", "Forensic Sciences", "Funding", "Future", "Goals", "Institution", "Intervention", "Interview", "Light", "Measures", "Mentors", "Methods", "North Carolina", "Phase", "Process", "Program Effectiveness", "Research", "Research Training", "Self Efficacy", "Series", "Students", "System", "Talents", "Training", "Training Activity", "Training Programs", "Underrepresented Minority", "Universities", "academic preparation", "cohort", "college", "computer science", "design", "efficacy research", "evidence base", "experience", "graduate school", "higher education", "mathematical sciences", "matriculation", "meetings", "minority trainee", "programs", "skills", "underrepresented minority student", "virtual" ], "approved": true } }, { "type": "Grant", "id": "11644", "attributes": { "award_id": "5R61AI169207-02", "title": "RNA Vaccine Innovations for TB: Targeting the Mucosa", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 23788, "first_name": "Jon T", "last_name": "Warren", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-22", "end_date": "2025-03-31", "award_amount": 538074, "principal_investigator": { "id": 23789, "first_name": "STEVEN GREGORY", "last_name": "REED", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1031, "ror": "", "name": "HDT BIO CORPORATION", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1031, "ror": "", "name": "HDT BIO CORPORATION", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "Our team - in collaboration with other vaccine developers - has been actively involved in tuberculosis (TB) vaccine discovery for the past three decades and led the team that developed the M72 vaccine that has provided proof of concept for effective subunit TB vaccines. Obstacles limiting commercial deployment of M72 include limited efficacy (~50% prevention of disease) and cost of goods for large-scale production. With these considerations in mind, our group developed a second-generation subunit vaccine, ID93, which consists of four protein antigens (M72 has two) formulated with a synthetic TLR4 targeted adjuvant formulation, as opposed to the natural product-based adjuvant contained in the M72 vaccine. ID93 has progressed to Phase 2 human clinical trials, with promising results and is currently in further development. Human immune responses measured against the ID93 components have been instructive and have allowed further antigen prioritization with a goal of complementing the antigens of M72. We have concurrently developed a new RNA vaccine platform - now in clinical development as a COVID-19 vaccine which may be approved in India in summer 2021 - and that induced potent cellular immunity and can be scaled in a cost-effective manner. Using a select panel of antigens, we will apply our RNA technology for inducing effective systemic and mucosal immune responses in mice and non-human primates. In addition, each of our RNA based adjuvants, TLR3 and RIG-I agonists, both being effective inducers of both innate and adaptive immune responses adds an innovative aspect. In this proposal, our innovation comes from three main areas of emphasis: First is optimization of the RNA vaccine technology by using new replicons and delivery systems. Second is applying RNA vaccination with subunit protein/adjuvant boosting, using adjuvants of known efficacy (TLR4 agonists) in comparison with novel adjuvants that signal through the TLR-3 or RIG-I pathways. Neither of these have been exploited extensively for infectious disease vaccines - particularly in the area of mucosal immunity. The third area comes from innovation in manufacturing and supply: We have novel processes for the production of TBRNA that were transferred to India (Gennova) and Brazil (CIMATEC). Gennova has already produced 1 million doses, with a target of 100 million by year-end, and has completed Phase 1 and 2 clinical trials in India. Similarly, we have acquired large- scale access to our adjuvant molecules (TLR4, TLR3, RIG-I), all synthetic, thus avoiding the intellectual property roadblock encountered with M72.", "keywords": [ "Address", "Adjuvant", "Aerosols", "Agonist", "Alphavirus", "Animals", "Antigens", "Area", "Brazil", "Businesses", "COVID-19 vaccine", "Cellular Immunity", "Clinical", "Clinical Trials", "Collaborations", "Combined Vaccines", "Communicable Diseases", "Complement", "Coupled", "Development", "Dose", "Formulation", "Generations", "Goals", "Human", "Immune response", "Immunity", "Immunization", "India", "Innate Immune Response", "Intellectual Property", "Intramuscular", "Kinetics", "Lipids", "Lung", "Measures", "Mind", "Mucosal Immune Responses", "Mucosal Immunity", "Mucous Membrane", "Mus", "Mycobacterium tuberculosis", "Mycobacterium tuberculosis antigens", "Natural Products", "Pathway interactions", "Phase", "Process", "Production", "Protein Subunits", "Proteins", "RNA", "RNA replication", "RNA vaccination", "RNA vaccine", "Recombinant Proteins", "Regimen", "Replicon", "Risk", "Route", "Safety", "Signal Transduction", "Subunit Vaccines", "System", "T-Lymphocyte", "TLR3 gene", "TLR4 gene", "Technology", "Testing", "Tuberculosis", "Tuberculosis Vaccines", "Vaccines", "adaptive immune response", "clinical development", "clinically relevant", "cost", "cost effective", "design", "disorder prevention", "immunogenicity", "improved", "in vivo", "innovation", "large scale production", "nanoparticle", "nonhuman primate", "novel", "prevent", "response", "success", "vaccination strategy", "vaccine candidate", "vaccine delivery", "vaccine development", "vaccine discovery", "vaccine distribution", "vaccine platform" ], "approved": true } }, { "type": "Grant", "id": "11645", "attributes": { "award_id": "5R01AI169239-02", "title": "Uptake, Safety and Effectiveness of COVID‐19 Vaccines during Pregnancy", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6243, "first_name": "BROOKE ALLISON", "last_name": "Bozick", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-08", "end_date": "2025-03-31", "award_amount": 383326, "principal_investigator": { "id": 7298, "first_name": "Annette Karena", "last_name": "Regan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 883, "ror": "https://ror.org/029m7xn54", "name": "University of San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 883, "ror": "https://ror.org/029m7xn54", "name": "University of San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Pregnant persons are at increased risk for severe COVD-19 illness compared to non-pregnant women of reproductive age, experiencing higher rates of admission to intensive care, mechanical ventilation and death. In addition to the direct impacts on the health of pregnant persons, there is growing evidence to suggest COVID-19 adversely impacts fetal and neonatal health. As of May 2021, three vaccines have been issued Emergency Use Approval in the US. However, because pregnant persons were excluded from initial Phase 3 clinical trials, data to confirm the safety and effectiveness of COVID-19 vaccination during pregnancy are lacking. Driven by this limited data, obstetric and public health governing bodies do not currently directly recommend vaccination for pregnant persons. The American College of Obstetricians and Gynecologists and the US Centers for Disease Control and Prevention (CDC) advise that COVID-19 vaccines should not be withheld from pregnant persons. As a result, the decision to vaccinate is made at the individual level, and pregnant persons express anxiety around making this decision. Additional data to inform the safety and effectiveness of COVID-19 vaccines administered during pregnancy would strengthen current clinical guidelines. Despite weak guidance, individuals are choosing to be vaccinated during pregnancy. As of 3 May 2021, 106,241 pregnant persons were reported as having received a COVID-19 vaccine through V-SAFE, the CDC’s active vaccine safety surveillance system. When surveyed, more than 50% of pregnant persons report an intention to receive a COVID-19 vaccine. Phase 2/3 clinical trial data are currently being gathered to evaluate safety and efficacy. While these clinical trial data are being collected, we have the opportunity to learn from large observational studies of pregnant persons who have chosen to be vaccinated. Leveraging existing national medical claims and electronic medical records for more than 870,000 pregnancies, we plan to conduct large-scale post-implementation cohort studies to evaluate the uptake, safety and effectiveness of COVID-19 vaccines administered during pregnancy. Completion of the proposed research will provide important epidemiological evidence on the safety and effectiveness of COVID-19 vaccination during pregnancy. This evidence will aid informed decision and policy-making around COVID-19 vaccination for pregnant persons.", "keywords": [ "2019-nCoV", "Admission activity", "Advisory Committees", "Age", "American College of Obstetricians and Gynecologists", "Anxiety", "COVID-19", "COVID-19 diagnosis", "COVID-19 impact", "COVID-19 vaccination", "COVID-19 vaccine", "Centers for Disease Control and Prevention (U.S.)", "Cessation of life", "Clinical", "Clinical Trials", "Cohort Studies", "Computerized Medical Record", "Data", "Databases", "Decision Making", "Discipline of obstetrics", "Disease", "Effectiveness", "Electronic Health Record", "Eligibility Determination", "Emergency Situation", "Ensure", "Epidemiology", "Event", "Exclusion", "FDA Emergency Use Authorization", "Fetal health", "Goals", "Guidelines", "Health", "Health Personnel", "Immunization", "Individual", "Infant", "Infant Health", "Infection", "Intensive Care", "Intention", "Learning", "Link", "Maternal Health", "Mechanical ventilation", "Medical", "Mothers", "Nature", "Observational Study", "Outcome", "Participant", "Passive Immunity", "Perinatal", "Perinatal mortality demographics", "Persons", "Phase", "Phase II/III Clinical Trial", "Phase III Clinical Trials", "Planned Pregnancy", "Policies", "Policy Making", "Population", "Population Group", "Pregnancy", "Pregnancy loss", "Premature Birth", "Probability", "Public Health", "Recommendation", "Reporting", "Research", "Risk", "Risk Factors", "SARS-CoV-2 exposure", "SARS-CoV-2 infection", "Safety", "Special Event", "Surveys", "System", "Time", "Update", "Vaccinated", "Vaccination", "Vaccines", "Woman", "adverse outcome", "adverse pregnancy outcome", "care providers", "experience", "fetal", "high risk", "implementation evaluation", "influenza virus vaccine", "interest", "maternal outcome", "neonatal health", "neonatal outcome", "neonate", "new technology", "policy implication", "policy recommendation", "post SARS-CoV-2 infection", "post implementation", "pregnant", "prevent", "programs", "reproductive", "severe COVID-19", "sociodemographics", "systematic review", "unvaccinated", "uptake", "vaccination outcome", "vaccination strategy", "vaccine acceptance", "vaccine safety", "variants of concern" ], "approved": true } }, { "type": "Grant", "id": "11646", "attributes": { "award_id": "5T34GM145505-02", "title": "U-RISE at PVAMU", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 27540, "first_name": "MARIE DEBORAHGAYNELLE", "last_name": "Harton", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-01", "end_date": "2027-03-31", "award_amount": 291506, "principal_investigator": { "id": 27547, "first_name": "E GLORIA CLAUDETTE", "last_name": "REGISFORD", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1640, "ror": "", "name": "PRAIRIE VIEW AGRI & MECH UNIVERSITY", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "URISE at PVAMU PI/PD: Regisford The increasing need for a well-trained STEM workforce, made more poignant during this COVID-19 pandemic, also requires a diverse population to meet the future needs and challenges in the biomedical sciences. An Undergraduate Research Training Initiative for Student Enhancement (U-RISE) program will reach a large racial and ethnic underrepresented (UR) population with disadvantaged socio-economic backgrounds and first-generation college students at Prairie View A&M University (PVAMU), a historically black university. Moreover, PVAMU's promotion of undergraduate engagement in research, and its established collaborations with surrounding research- intensive universities, provide a robust learning environment that will strongly support a U-RISE program. Although student enrollment in biomedical science disciplines such as Biology and Chemistry are relatively high, less than 10% declare an interest in graduate school; a conundrum that may be due to lack of exposure and preparation for the rigors of graduate school. Therefore, the overarching goal of this proposed U-RISE program is to enhance student participation and preparation in the biomedical sciences for matriculation into highly competitive PhD programs and ultimately, a biomedical science research career. This goal will be accomplished by the following specific objectives: (1) Provide an enriched interdisciplinary research culture that exposes all U-RISE trainees to hands-on research for three consecutive years; (2) Enhance the academic curriculum that fosters advancement of 80% of U-RISE at PVAMU trainees to a biomedical science graduate program and (3) Create a nurturing learning community by engaging U-RISE at PVAMU trainees in a multidimensional mentoring program, that will lead to improved retention (90% of U-RISE trainees) and graduation rate (90% of U-RISE trainees). Program elements will include professional skills development of all U- RISE trainees to enhance their competitiveness. We have built a multidisciplinary team of faculty, research professors/scientists, and external collaborators to create a nurturing and stimulating culture that will evoke evidence-based student support and motivation practices. Each year, four sophomores will be selected to join the U-RISE at PVAMU program. Selection of U-RISE trainees will be based on the following criteria: the students' academic record, member of a racial and ethnic UR population, a declared major in a biomedical science discipline, and a desire to attend graduate school in the biomedical sciences. The expected outcomes are (1) an increase in the number of students who become engaged in biomedical science research; (2) an extensive academic preparation of U-RISE at PVAMU trainees for matriculation into a competitive graduate program within one year after graduation; and (3) the creation of a replicable, transportable, evidence-based model that promotes preparation of undergraduates from UR populations for biomedical science research careers. Ultimately, the U-RISE at PVAMU program will contribute to increased diversity in the biomedical sciences workforce.", "keywords": [ "Biology", "COVID-19 pandemic", "Chemistry", "Collaborations", "Dimensions", "Discipline", "Doctor of Philosophy", "Educational Curriculum", "Elements", "Enrollment", "Ethnic Origin", "Faculty", "First Generation College Students", "Fostering", "Future", "Goals", "Graduation Rates", "Historically Black Colleges and Universities", "Interdisciplinary Study", "Mentors", "Modeling", "Motivation", "Outcome", "Population Heterogeneity", "Preparation", "Race", "Research", "Research Training", "STEM career", "Science", "Scientist", "Students", "Training", "Underrepresented Populations", "Universities", "academic preparation", "career", "community engagement", "educational atmosphere", "evidence base", "graduate school", "hands on research", "improved", "interest", "learning community", "matriculation", "member", "multidisciplinary", "professor", "programs", "skill acquisition", "socioeconomic disadvantage", "student participation", "undergraduate research", "undergraduate student" ], "approved": true } }, { "type": "Grant", "id": "11647", "attributes": { "award_id": "5F31AT011988-02", "title": "Exploring the Potential of Natural Products to Combat COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Complementary and Integrative Health (NCCIH)" ], "program_reference_codes": [], "program_officials": [ { "id": 26174, "first_name": "Patrick Colby", "last_name": "Still", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-01", "end_date": "2024-12-31", "award_amount": 47694, "principal_investigator": { "id": 26175, "first_name": "Caitlin Jaime", "last_name": "Risener", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "As of August 2021, the coronavirus disease COVID-19, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has infected more than 200 million people across the globe, causing more than 600,000 deaths in the USA and 4.2 million worldwide. Though vaccines have become available, vaccinated individuals can still spread the disease to unvaccinated and vulnerable populations. As vaccination rates in the United States remain low, emerging variants that may evade the vaccine are a new risk. Identifying novel preventative agents from traditional medicine could lead to the development of a readily available, cost-effective, and safe dietary intervention against COVID-19. During the pandemic, individuals have turned to herbal supplements to prevent COVID-19. There are published in silico studies and a few in vitro studies on these extracts, but the science to support natural products’ (NPs) use to prevent viral infection is still incomplete. The Quave Natural Product Library (QNPL) is a collection of over 2,000 botanical and fungal extracts, including the 40 most used natural supplements in the USA. Viral entry, in which SARS-CoV-2 attaches to the Angiotensin-Converting Enzyme 2 (ACE2) cell surface receptor found on endothelial cells, pneumocytes (type 1 and 2), and ciliated bronchial epithelial cells, presents an attractive option for preventatives. I have screened 2,000 extracts from the QNPL against SARS-CoV- 2 pseudotyped virus system to test which extracts inhibit viral entry. Mammalian cell cytotoxicity assays measuring Lactate Dehydrogenase (LDH) formation were run in parallel to ensure inhibition was not due to cell death. This proposal employs a multi-faceted approach to identify agents with direct-acting antiviral properties using a one-of-a-kind natural product library. Three extracts with potent bioactivity as direct-acting antiviral agents without apparent toxicity were selected after screening the QNPL. Bioassay guided fraction coupled to LC- MS/MS molecular networking analysis will be used for the identification of compounds with direct-acting antiviral activity. Compounds will be further isolated using preparative HPLC and structurally elucidated by NMR and X- crystallography to determine the absolute structure of the viral inhibitor. The fractions and isolated compounds will be tested across emerging variants in relevant cell lines and in live virus to further understand activity. Additionally, I will undertake mechanism of action studies utilizing biolayer interferometry and ELISA assays. These studies will result in the identification of NPs with the potential to block SARS-CoV-2 viral entry in relevant human cells, enhancing understanding of the preventative value of plant NPs for COVID-19 and other viruses. This will enable formulation of a bioactive dietary supplement, prioritization of leads for a medicinal chemistry campaign, and identification of tool compounds to query these pathways.", "keywords": [ "2019-nCoV", "A549", "ACE2", "Antiviral Agents", "Binding", "Biological Assay", "Biological Sciences", "Botanicals", "COVID-19", "COVID-19 prevention", "COVID-19 treatment", "Cell Death", "Cell Line", "Cell Surface Receptors", "Cell model", "Cells", "Cessation of life", "Chemicals", "China", "Chromatography", "Ciliated Bronchial Epithelial Cell", "Collaborations", "Collection", "Communicable Diseases", "Contracts", "Coupled", "Crystallography", "Data", "Development", "Diet", "Dietary Intervention", "Disease", "Dose", "Edible Plants", "Endothelial Cells", "Ensure", "Enzyme-Linked Immunosorbent Assay", "Epithelial Cells", "Ethnobotany", "Exhibits", "Formulation", "Fractionation", "Goals", "Health Care Costs", "Health Professional", "Herbal supplement", "High Pressure Liquid Chromatography", "Human", "Immune response", "In Vitro", "Indigenous", "Individual", "Infection", "Inflammatory", "Interferometry", "Lactate Dehydrogenase", "Lentivirus", "Libraries", "Luciferases", "Lung", "Mammalian Cell", "Measures", "Medicinal Plants", "Medicine", "Modeling", "Molecular", "Natural Compound", "Natural Products", "Natural Supplement", "Pathway interactions", "Persons", "Pharmaceutical Chemistry", "Pharmacognosy", "Plants", "Plaque Assay", "Population", "Process", "Property", "Province", "Publishing", "Recording of previous events", "Reporter", "Research", "Resistance", "Resolution", "Resources", "Risk", "Running", "SARS-CoV-2 infection", "SARS-CoV-2 inhibitor", "SARS-CoV-2 spike protein", "SARS-CoV-2 variant", "Safety", "Science", "Serial Passage", "Severity of illness", "Standardization", "Structure", "Surface", "System", "Techniques", "Testing", "Therapeutic", "Toxic effect", "Traditional Medicine", "United States", "Vaccinated", "Vaccination", "Vaccinee", "Vaccines", "Variant", "Viral", "Viral Physiology", "Virus", "Virus Diseases", "Virus Inhibitors", "Vulnerable Populations", "X-Ray Crystallography", "clinically relevant", "combat", "coronavirus disease", "cost effective", "cytotoxicity", "dietary", "dietary supplements", "efficacy validation", "high throughput screening", "in silico", "insight", "novel", "pandemic disease", "pneumocyte", "prevent", "receptor", "receptor binding", "repository", "screening", "secondary metabolite", "symptom treatment", "tool", "unvaccinated", "vaccine access", "vaccine hesitancy", "viral entry inhibitor" ], "approved": true } }, { "type": "Grant", "id": "11648", "attributes": { "award_id": "5U01MD017867-02", "title": "Statistical adjustments of sample representation in community-level estimates of COVID-19 transmission and immunity", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 6029, "first_name": "JARRETT AINSWORTH", "last_name": "Johnson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-01", "end_date": "2025-12-31", "award_amount": 562066, "principal_investigator": { "id": 7436, "first_name": "Yajuan", "last_name": "Si", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "Throughout the COVID-19 pandemic, government policy and healthcare implementation responses have been guided by reported positivity rates and vaccination rates in the community. The selection bias of these test data questions their validity as measures of the actual viral incidence in the community and as predictors of clinical burden. Publicly available vaccination data are frequently cited as a proxy for population immunity, but this metric ignores the effects of naturally-acquired immunity. The health disparities concerning asymptomatic and symptomatic patients are not yet studied. The proposal develops a valid metric to estimate the true viral incidence and naturally/vaccine-acquired immunity prevalence in the community, examine the health disparities and social inequality, and monitor the epidemic over time as an operational surveillance system. The approach collects routine testing data on SARS-CoV-2 exposure and antibody seropositivity among patients in a hospital system and performs statistical adjustments of sample representation using multilevel regression and poststratification (MRP), which adjusts for measured differences between the sample and population and also yields stable small area estimates. The data collection and analysis procedure can provide information to entire communities with generalizability and focus on burdens within specific demographics, with close attention to vulnerable populations on disparities across health outcomes, social determinants, and behaviors. In particular, the research will yield group-specific estimates of disparities with respect to asymptomatic and symptomatic patients and how these discrepancies may impact the socio-demographically dependent spread of disease and its subsequent treatment. The MRP adjustment will be made publicly accessible via a web interface and promote broad investigations with integrated data sources toward a national study.", "keywords": [ "2019-nCoV", "American", "Antibodies", "Area", "Attention", "Behavior", "Black race", "COVID testing", "COVID-19 pandemic", "COVID-19 patient", "Calibration", "Communities", "Community Hospitals", "Community Surveys", "Data", "Data Analyses", "Data Collection", "Data Set", "Data Sources", "Disease", "Electronic Health Record", "Epidemic", "Ethnic Origin", "Foundations", "Future", "Geography", "Government", "Guidelines", "Health", "Health behavior and outcomes", "Healthcare", "Hospitals", "Immunity", "Incidence", "Indiana", "Individual", "Inequality", "Intervention", "Investigation", "Knowledge", "Link", "Locales", "Measures", "Methodology", "Methods", "Monitor", "Outcome", "Pathway interactions", "Patients", "Phase", "Policies", "Policy Maker", "Population", "Prevalence", "Procedures", "Proxy", "Public Health", "Race", "Reporting", "Reproducibility", "Research", "Rural", "SARS-CoV-2 exposure", "SARS-CoV-2 immunity", "SARS-CoV-2 transmission", "Sampling", "Selection Bias", "Sensitivity and Specificity", "Seroprevalences", "Statistical Data Interpretation", "Statistical Methods", "Stratification", "Subgroup", "System", "Testing", "Time", "Vaccination", "Vaccines", "Variant", "Viral", "Virus Diseases", "Vulnerable Populations", "Work", "acquired immunity", "clinical predictors", "comorbidity", "coronavirus disease", "data harmonization", "data integration", "demographics", "future epidemic", "health care service utilization", "health disparity", "member", "pandemic disease", "predictive modeling", "response", "rural setting", "screening", "seropositive", "sex", "social", "social determinants", "social inequality", "sociodemographics", "socioeconomics", "suburb", "trend", "vaccine access", "viral transmission", "web based interface", "web interface" ], "approved": true } }, { "type": "Grant", "id": "11649", "attributes": { "award_id": "5R01AI163142-02", "title": "A multipronged investigation of SARS-CoV-2 genome packaging", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 26420, "first_name": "MARY KATHERINE", "last_name": "Bradford", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-16", "end_date": "2027-03-31", "award_amount": 625894, "principal_investigator": { "id": 7461, "first_name": "Andrea", "last_name": "Soranno", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic, caused by the virus SARS-CoV-2, represents an acute and ongoing threat to human life. A detailed molecular understanding of the viral life cycle is necessary to illuminate clinically accessible processes that can be targeted for therapeutic intervention. The Nucleocapsid (N) protein is a 420-residue multidomain protein with both folded and disordered regions that underlies genome packaging, an essential step in the virion lifecycle. N protein mediates cytosolic genome packaging by binding to and compacting genomic RNA in a process apparently conserved across the coronaviridae family. Our ability to disrupt genome packaging is limited by the absence of a molecular understanding of these processes. To address this knowledge gap, our proposal is focused on the molecular biophysics that underlies how N protein drives genome compaction. N protein is highly multivalent; it can simultaneously bind to both itself and RNA via a number of distinct interaction sites. Multivalency is encoded across both folded domains and intrinsically disordered regions. While there has been substantial work on the folded domains in other coronaviruses, the molecular biophysics of the disordered regions has been largely ignored. We hypothesize N protein multivalency underlies the molecular basis of RNA compaction, and that the three disordered regions play key roles in determining multivalency, binding affinity, and RNA binding specificity. Through the combination of single-molecule fluorescence and force spectroscopy, ensemble methods, and all-atom simulation, we will dissect the molecular details that underlie these interactions. We also present a novel approach to small-molecule screening that leverages the formation of phase separated protein:RNA liquid droplets as a readout for genome compaction. Our work will offer high-resolution structural insight into the physical basis for two critical steps in the viral life cycle, as well as reveal small molecules that can attenuate genome compaction. More generally, by focusing on fundamental biophysical phenomena that empirically explain behavior from other distant coronaviruses, we believe that our conclusions will be broadly transferable to existing coronaviruses that represent major public health threats (e.g., SARS, MERS) but also to future novel zoonotic coronaviruses.", "keywords": [ "2019-nCoV", "Acute", "Address", "Affinity", "Antiviral Agents", "Attenuated", "Behavior", "Binding", "Biological Assay", "Biophysics", "COVID-19 pandemic", "Cells", "Clinical", "Coronavirus", "Coupled", "Data", "Development", "Diameter", "Disease", "Dissection", "Distant", "Encapsulated", "Family", "Fluorescence", "Fluorescence Spectroscopy", "Future", "Genome", "Goals", "Human", "In Vitro", "Investigation", "Knowledge", "Lead", "Length", "Life", "Life Cycle Stages", "Liquid substance", "Measurement", "Measures", "Mediating", "Methods", "Microscope", "Microscopy", "Middle East Respiratory Syndrome", "Molecular", "N Domain", "Nucleic Acids", "Nucleocapsid", "Phase", "Physical condensation", "Play", "Process", "Proteins", "Public Health", "Publishing", "RNA", "RNA Binding", "RNA Viruses", "RNA-Binding Proteins", "RNA-Protein Interaction", "Resolution", "Role", "SARS-CoV-2 genome", "Severe Acute Respiratory Syndrome", "Site", "Specificity", "Spectrum Analysis", "Tertiary Protein Structure", "Testing", "Therapeutic", "Therapeutic Intervention", "Vaccines", "Viral", "Viral Genome", "Viral Packaging", "Virion", "Virus", "Virus Replication", "Work", "betacoronavirus", "coronavirus therapeutics", "design", "experimental study", "genomic RNA", "high throughput screening", "insight", "novel", "novel strategies", "optic trap", "optical traps", "pandemic coronavirus", "prevent", "screening", "simulation", "single molecule", "small molecule", "targeted treatment", "zoonotic coronavirus" ], "approved": true } }, { "type": "Grant", "id": "11650", "attributes": { "award_id": "5R01HS028397-02", "title": "Evaluating the Impact of Telemedicine on Ambulatory Care", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Agency for Healthcare Research and Quality (AHRQ)" ], "program_reference_codes": [], "program_officials": [ { "id": 22656, "first_name": "Chunliu", "last_name": "Zhan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-08", "end_date": "2027-01-31", "award_amount": 353406, "principal_investigator": { "id": 23795, "first_name": "Chandy Skaria", "last_name": "Ellimoottil", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23796, "first_name": "Michael Patrick", "last_name": "Thompson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "BACKGROUND: During the first six months of 2020, 10 million Medicare beneficiaries used telemedicine services compared to only 134,000 during the first six months of 2019. Telemedicine policy changes during the COVID-19 pandemic catalyzed a major transformation of ambulatory care delivery that is sustained—currently 1 out of 5 ambulatory care visits are performed through telemedicine. While state and federal agencies have long positioned telemedicine as a means to improve health, post-pandemic telemedicine policymaking is hindered due to the scarcity of evidence on the broad scale impact of telemedicine on healthcare access, quality and costs. For instance, it is challenging to enact permanent telemedicine policies that facilitate the equitable use of telemedicine without an understanding of patient, provider and market barriers that impede its use. Furthermore, while widespread telemedicine use has the potential to improve clinical outcomes such as preventable hospital admission rates, there is a lack of empirical data on this topic. Finally, while essential for policymaking, the broad scale impact of telemedicine use on Medicare spending and utilization has not been previously studied. The dramatic increase in telemedicine use as a result of healthcare policies enacted during the COVID-19 pandemic provides an unprecedented opportunity to address these long-standing knowledge gaps. OVERALL STRATEGY: In this study, we propose using a contemporary, national cohort of Medicare beneficiaries supplemented with detailed provider and market-level data to investigate factors associated with telemedicine use, and the impact of telemedicine on ambulatory care outcomes and healthcare spending. RESEARCH AIMS: 1) To identify patient, provider and market-level determinants of telemedicine use. We will explore heterogeneity in telemedicine use across specific populations of interest, including beneficiaries that are rurally located, elderly, racial/ethnic minorities, or socioeconomically disadvantaged. 2) To evaluate the association between practice-level telemedicine use and hospital admissions for ambulatory care sensitive conditions. 3) To evaluate the impact of clinician-level telemedicine use on 30-day total per capita costs. IMPACT: Findings from this study will directly inform major areas of uncertainty and provide key evidence to inform telemedicine policymaking.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1383, "pages": 1397, "count": 13961 } } }